Qprotyn Inc
Qprotyn is dedicated to advancing biologics delivery by transforming monoclonal antibody (mAb) administration from intravenous (IV) to subcutaneous (SubQ) methods. Their innovative platform technology, HILOPRO®, utilizes GRAS excipients to enable high-concentration, low-viscosity formulations that support multiple dosing options, enhance patient convenience, and reduce injection frequency. The company's mission is to improve patient experience and market acceptance of biologics through safe, simple, and effective subcutaneous delivery solutions.
Industries
Nr. of Employees
small (1-50)
Qprotyn Inc
Cambridge, Massachusetts, United States, North America
Products
Patented viscosity-reduction formulation platform
A platform technology for producing high-concentration, low-viscosity monoclonal antibody formulations intended to enable subcutaneous delivery and reduce administration volume and frequency.
Patented viscosity-reduction formulation platform
A platform technology for producing high-concentration, low-viscosity monoclonal antibody formulations intended to enable subcutaneous delivery and reduce administration volume and frequency.
Services
Limited investigational licensing that allows partner scientists to evaluate formulations in their own laboratory using provided templates and confidentiality agreements.
Accelerated formulation screening and proof-of-concept generation for candidate monoclonal antibodies with a targeted eight-week timeline.
Negotiation and execution support for licensing agreements and partnership engagement to deploy the viscosity‑reduction technology across biologics pipelines.
Limited investigational licensing that allows partner scientists to evaluate formulations in their own laboratory using provided templates and confidentiality agreements.
Accelerated formulation screening and proof-of-concept generation for candidate monoclonal antibodies with a targeted eight-week timeline.
Negotiation and execution support for licensing agreements and partnership engagement to deploy the viscosity‑reduction technology across biologics pipelines.
Expertise Areas
- Subcutaneous delivery of high-concentration biologics
- High-concentration/low-viscosity formulation development
- Formulation–device co-development for delivery systems
- Rapid formulation proof-of-concept and screening
Key Technologies
- Viscosity-reduction formulation platform (patented)
- High-concentration protein formulation
- GRAS excipient–based stabilization
- Subcutaneous delivery system design
News & Updates
Delivering High-Concentration Biologics Subcutaneously
Discussion on biologics in ophthalmology at the American Academy of Optometry 2021 annual meeting.
In May 2020, Bhami’s Research Laboratory was granted a US patent for a technology for high concentration formulations with reduced viscosity.
Delivering High-Concentration Biologics Subcutaneously
Discussion on biologics in ophthalmology at the American Academy of Optometry 2021 annual meeting.
In May 2020, Bhami’s Research Laboratory was granted a US patent for a technology for high concentration formulations with reduced viscosity.